ASH 2023: The Impact of Fitness and Dose Intensity on Safety and Efficacy Outcomes after Venetoclax-Obinutuzumab in Previously Untreated CLL
A comprehensive analysis of Venetoclax-Obinutuzumab (Ven-Obi) in treating chronic lymphocytic leukemia (CLL) reveals its effectiveness and tolerability across different patient profiles.
Få tilgang
Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.
- Få tilgang
- Hvis du allerede har en profil: Logg in
